Positive Trial Results: Absci reported encouraging interim Phase 1 data for its ABS-201 candidate targeting hair loss, showing a clean safety profile with no serious adverse events in early volunteers. This development triggered a notable single-day stock advance amid broader biotech sector movements.
Analyst Sentiment Shifts: Research firms highlighted the data as de-risking for further indications like endometriosis, prompting price target increases and reiterated buy ratings from multiple Street voices. Observers noted the timing alongside a capital raise as a potential platform validation step.
Investor Chatter Intensifies: Social media threads reflect widespread excitement over the clinical update, with frequent mentions of Absci's AI-driven discovery approach and partnerships. Overall tone leans strongly bullish as participants debate the implications for upcoming milestones.
Note: This discussion summary was generated from an AI condensation of post data.
Absci Insider Trading Activity
Absci insiders have traded $ABSI stock on the open market 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ABSI stock by insiders over the last 6 months:
- ANDREAS BUSCH (Chief Innovation Officer) purchased 100,000 shares for an estimated $229,000
- MENELAS N PANGALOS purchased 37,453 shares for an estimated $200,748
- SEAN MCCLAIN (Chief Executive Officer) sold 26,761 shares for an estimated $80,015
- ZACHARIAH JONASSON (CFO / CBO) sold 17,496 shares for an estimated $52,313
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
EARLY ACCESS
Receive ABSI Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
Absci Hedge Fund Activity
We have seen 94 institutional investors add shares of Absci stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,038,504 shares (-94.5%) from their portfolio in Q1 2026, for an estimated $6,115,512
- SCHONFELD STRATEGIC ADVISORS LLC removed 2,017,462 shares (-85.9%) from their portfolio in Q1 2026, for an estimated $6,052,386
- SIREN, L.L.C. added 1,800,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,400,000
- CITADEL ADVISORS LLC removed 1,539,213 shares (-79.2%) from their portfolio in Q1 2026, for an estimated $4,617,639
- TWO SIGMA INVESTMENTS, LP added 1,480,350 shares (+104.4%) to their portfolio in Q1 2026, for an estimated $4,441,050
- STATE STREET CORP added 1,333,981 shares (+22.3%) to their portfolio in Q1 2026, for an estimated $4,001,943
- MARSHALL WACE, LLP added 1,219,052 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,657,156
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Absci Price Targets
Multiple analysts have issued price targets for $ABSI recently. We have seen 6 analysts offer price targets for $ABSI in the last 6 months, with a median target of $12.5.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $16.0 on 06/25/2026
- Kambiz Yazdi from BTIG set a target price of $13.0 on 06/24/2026
- Gil Blum from Needham set a target price of $11.0 on 06/24/2026
- Vamil Divan from Guggenheim set a target price of $15.0 on 06/15/2026
- Mani Foroohar from Leerink Partners set a target price of $12.0 on 06/04/2026
- Srikripa Devarakonda from Truist Securities set a target price of $11.0 on 05/08/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Absci Stock (ABSI) Opinions on Positive Phase 1 Data for ABS-201
Positive Trial Results: Absci reported encouraging interim Phase 1 data for its ABS-201 candidate targeting hair loss, showing a clean safety profile with no serious adverse events in early volunteers. This development triggered a notable single-day stock advance amid broader biotech sector movements.
Analyst Sentiment Shifts: Research firms highlighted the data as de-risking for further indications like endometriosis, prompting price target increases and reiterated buy ratings from multiple Street voices. Observers noted the timing alongside a capital raise as a potential platform validation step.
Investor Chatter Intensifies: Social media threads reflect widespread excitement over the clinical update, with frequent mentions of Absci's AI-driven discovery approach and partnerships. Overall tone leans strongly bullish as participants debate the implications for upcoming milestones.
Note: This discussion summary was generated from an AI condensation of post data.
Absci Insider Trading Activity
Absci insiders have traded $ABSI stock on the open market 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ABSI stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Absci Hedge Fund Activity
We have seen 94 institutional investors add shares of Absci stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Absci Price Targets
Multiple analysts have issued price targets for $ABSI recently. We have seen 6 analysts offer price targets for $ABSI in the last 6 months, with a median target of $12.5.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »